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1. Abstract 
Background: 
Malaria prevention methods for travelers to low or moderate malaria risk areas varies and 
remains controversial. Standby Emergency Treatment (SBET) for malaria is one possible 
strategy increasingly recommended since 1988 with little evidence on its effectiveness or how 
it is truly being used.  
Methods: 
A systematic review and meta-analysis were performed based on a structured search in 
Embase, Medline, PubMed, Cochrane, and Web of Science on September 7, 2018. The 
primary outcome was the overall prevalence of SBET use in travelers, and secondary 
outcomes were the proportion carrying SBET, the response to fever (use of SBET, health 
facility attendance, use of malaria rapid diagnostic test [mRDT]), adverse events to SBET, 
and the proportion using SBET incorrectly (incorrect dosage/duration). The pooled SBET use 
prevalence was analyzed using a random-effects model. A descriptive summary was done to 
present secondary outcomes. The study protocol was registered with PROSPERO 
CRD42018103703. 
Results: 
11 studies were eligible for inclusion among the 1027 titles identified by our search. The 
studies included 7/11 prospective cohort studies that recruited pre-travel clinic attendees in 
Europe, and 4/11 cross-sectional studies, of which 3 recruited travelers at airports before their 
return home from South-East-Asia and Africa, and 1 from an employee registry including 
long-term travelers. The overall pooled prevalence of SBET use among the 26’403 travelers 
was 2.5% (95%CI 1.1%-4.3%; range 0.4%-10.8%). There was significant variation in the 
proportion of travelers carrying SBET medication (40%-100%), the proportion of travelers 
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with appropriate response to fever (23%-100%), adverse events (0%-33%) and incorrect 
dosage/duration of SBET (0%-100%). 
Conclusions: 
Adherence to the proposed recommendations for SBET use, notably the response to fever, 
was poor. If the use of SBET is to be pursued, modifications to the current SBET strategy 
should be considered, such as better selection of travelers at higher risk for malaria, and the 
potential addition of mRDTs. 
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2. Introduction 
The number of international travelers to countries at risk of malaria transmission is estimated 
to be more than 125 million per year (1).  The importance of proper preventive measures 
against malaria is emphasized by a case fatality rate of malaria among international travelers 
to be around 1% (2, 3). While chemoprophylaxis remains the standard preventive measure for 
international travel to countries at high-risk of malaria transmission, preventive measures for 
travelers to low or moderate-risk areas, most notably the use of standby emergency treatment 
(SBET), remains controversial (4-6). 
SBET is defined as the self-administration of anti-malarial drugs in emergency situations as a 
life-saving measure when malaria is suspected (7). The World Health Organization (WHO) 
(1) proposes the use of SBET among:  
a) travelers staying in remote locations unable to seek medical attention within 24 hours of the 
onset of fever,  
b) travelers in some occupational groups making frequent short stops to countries or areas 
with malaria risk over a prolonged period of time 
 c) short-term travelers spending ≥ one week in certain remote rural areas where there is very 
low risk of infection.  
Areas of low to moderate risk of malaria infection is difficult to define (8), some defining it as 
an annual incidence of malaria in the indigenous population of less than 10 per 1000 
individuals, or between 1-10 per 100 000 travelers (9, 10), while others use a combination of 
various surveillance data (11, 12).  
Those in favor of SBET argue that malaria can be lethal if not treated promptly, could reduce 
the need for daily or weekly chemoprophylaxis, and the rise of counterfeit drugs justifies that 
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travelers carry their own supply of malaria medication. Furthermore, travelers to low or 
moderate risk areas often prefer the use of SBET as opposed to other prevention strategies 
(13). The use of SBET has been proposed to be used as a treatment in combination with 
chemoprophylaxis (11, 12) or as a stand-alone treatment in specific circumstances (1). 
Opponents of SBET propose daily chemoprophylaxis for low or moderate malaria endemic 
areas because of the potential fast progression to severe disease even when treated promptly, 
and question as well travelers’ capabilities to respond appropriately to the SBET 
recommendations. Others argue that mosquito protection is sufficient for such areas given the 
easy access to health facilities in touristic areas, the risk of neglecting other lethal diseases 
when using SBET, and the wasted resources of unused anti-malarial drugs (4, 14).  
SBET was first prescribed in Swiss travelers in 1988 (15) and progressively adopted by other 
countries around the globe. As malaria risk worldwide continues to decline (16), more travel 
destinations will become low to moderate malaria risk areas, thus possibly increasing the 
prescription of SBET as already seen (17, 18). While SBET has been prescribed for over 30 
years now, we have little evidence on how it is truly used nor how effective it is in travelers 
around the world. The goal of this systematic review and meta-analysis is to better understand 
how SBET is currently used among travelers to malaria endemic countries, and notably how 
travelers apply SBET recommendations, with the aim of reassessing the relevance of SBET as 
a preventive strategy. 
 
3. Methods 
Methods of this analysis were specified in advanced and published in a protocol on 
PROSPERO on September 6, 2018, CRD42018103703 (19). This systematic review followed 
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the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines (see Supplementary Material S1 for PRISMA checklist) (20).  
Search strategy 
We searched the following five databases for relevant articles: Embase.com, Medline Ovid 
SP, PubMed, Cochrane Library Wiley, and Web of Science – Core collection on September 7, 
2018. The search performed combined three terms: malaria; self-treatment/standby 
emergency treatment; and traveler (see Supplementary Material S2 for full details on search 
strategies). Reference lists of retained articles were also reviewed. 
Eligibility criteria 
We included prospective cohort and cross-sectional studies that documented primary data on 
the number of travelers using malaria SBET out of the number prescribed or carrying SBET. 
No language, or publication date restrictions were imposed. 
The study population included all adult and children travelers from non-endemic malaria 
countries to malaria endemic countries. Travelers included short and long-term travelers, 
workers, employees, volunteers, military personnel or expatriates visiting a malaria endemic 
countries.  
The primary outcome was SBET use prevalence, defined as the number of travelers using 
SBET out of the number carrying SBET. In prospective observational studies in which the 
number of travelers carrying SBET was not documented, we used the number of malaria 
SBET prescribed. 
Secondary outcomes included when available, the proportion of travelers carrying SBET 
among those that were prescribed SBET, the number of SBET carriers with appropriate 
response to fever (ingesting SBET, using mRDT and/or seeking a health professional), the 
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number of adverse events related to SBET use, and the number of SBET users with 
inappropriate SBET use (incorrect dose, incorrect duration). Given the expected limitation of 
data available for these outcomes and the heterogeneity of studies, a meta-analysis was not 
done for secondary outcomes, but rather we focused on describing the results of the individual 
studies.  
Study selection, data collection and analysis 
The two reviewers (RT, BG) independently scanned the titles and abstracts of studies 
identified in the computerized search to exclude publications that clearly did not meet the 
inclusion criteria. Independent full text review was also performed by both authors based on 
the review inclusion/exclusion criteria. Translations for the full-text review were undertaken 
for 4 studies in German and one in Chinese. We contacted authors to clarify information or to 
retrieve missing information when needed (8/11 studies). The data, as defined by the protocol, 
was extracted by one review author in a piloted form and the second author checked the 
extracted data. All disagreements were resolved by consensus.  
The two reviewers (RT and BG) independently assessed the methodological quality of the 
included papers using a modified version of the Newcastle-Ottawa Scale (mNOS) checklist 
(21). In the modified version (Supplementary Material S3) the items relating to controls, 
comparability, and presence of outcome at start of study were eliminated due to the nature of 
the type of studies included. 
Data for the meta-analysis were analyzed using STATA version 15.1. Stabilizing the variance 
of individual studies was performed using the Freeman-Turkey Double Arcsine 
Transformation (22). Due to the expected differences between study population 
characteristics, a random-effect model using the method of DerSimonian & Laird was applied 
to pool SBET use prevalence (23). Data for the primary outcome was presented using a forest 
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plot of SBET use prevalences. Heterogeneity was evaluated by measuring the variation 
between studies using the I2 statistic, and explored using a funnel plot and Egger’s test to 
assess for small-study effects. 
A subgroup analysis was predetermined to explore heterogeneity using the following 
categories: short versus long-term travelers, by study design, by period of study (last year), by 
type of recruitment, by use of mRDT, and by mNOS. Due to the small number of studies  
(less than ten studies per subgroup category), subgroup analysis was not done, as 
recommended by the Cochrane handbook for systematic reviews (24). 
 
4. Results 
Study selection and characteristics 
The search identified 1847 studies, for which 1027 remained after adjusting for duplicates. 53 
studies were included for full text review, including 8 from cross references of the final 
studies. 11 studies were identified for inclusion in the meta-analysis (15, 25-34). See flow 
diagram Figure 1. 
Among the 11 studies included, 7/11 were prospective cohort studies, and 4/11 were cross-
sectional studies. Five studies included a study period between 1985 and 1995, two studies 
between 1996 and 2006, and four between 2007 and 2017 (Table 1). Publication dates ranged 
from 1990 to 2017 (median, 2000). 
The included studies involved 26’403 travelers carrying SBET, of which 65% were from the 
Steffen et al. cross-sectional study published in 1990 (26). 9/11 studies included mostly short- 
term travelers (<3 months), with two studies that included mostly long-term travelers; 
Roukens et al. studied long-term international oilfield service employees (31), and Berthod et 
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al. long-term travelers (69%), travelers to remote areas (57%), humanitarian workers (11%), 
short-stay frequent travelers (4%), and travelers not willing to take malaria chemoprophylaxis 
(10%) for whom SBET was proposed together with mRDTs (32).  Among the cross-sectional 
studies, three recruited travelers from Europe (25, 26, 30) and North America (25) at airports 
before flying back from their travel destination, while all the prospective cohort studies only 
included travelers recruited from their pre-travel consultations in Europe [Sweden (27), 
Germany (28, 29, 33), Switzerland (15, 32) and Spain (34)].   
TABLE 1 
The quality assessment using the mNOS found two studies that received 3/4 stars, four studies 
received 2/4 stars, four studies received 1/4, and one study received 0/4 stars (Supplementary 
Material S4). The major source of bias in all studies, came from the assessment of outcomes, 
as they were all self-reported, and ascertainment of exposure, as most were written self-
reports. 
Primary outcome: SBET use prevalence  
The overall pooled SBET use prevalence of the 26’403 SBET carriers in 11 studies was 2.5% 
(95%CI 1.1%-4.3%). We detected significant heterogeneity within the studies (I2 = 97.2%; 
Chi2 = 357.41, df = 10) (Figure 2). A notable outlier that had a significantly higher SBET use 
prevalence included the Roukens et al. study, which enrolled international oilfield service 
employees who were mostly stationed for a long period in low to high malaria risk areas, a 
completely different population compared to the other studies (31). When excluding this 
study, the overall pooled SBET use prevalence of the remaining 10 studies dropped to 1.8% 
(95% CI 0.8%-3.2%) with a slight reduction in heterogeneity (I2 = 95.8%). A funnel plot was 
drawn to explore this heterogeneity which did not find any evidence of a small study bias, 
confirmed by the Egger’s test (p=0.53) (Sup. Mat. S5).  
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Figure 2: Forest plot of SBET use prevalence using a random-effects model 
Secondary outcomes: SBET carriage, response to fever, adverse events due to SBET, 
incorrect dosage/duration of SBET 
The data on the proportion of travelers carrying SBET out of those receiving a SBET 
prescription were available in 6/11 studies (table 2). All travelers carried the prescribed 
malaria medication for SBET in studies which either provided the drug as part of the study 
(15), provided the medication from the employer (31), or by ensuring SBET medication was 
bought when paying for the travel consultation immediately after the consultation (32). In the 
other studies, travelers had to buy their medication from a pharmacy after their travel 
consultation, with proportions as low as 38% (34) to as high as 72.6% (33). In the Ropers et 
al. cross-sectional study, they found that 65.9% (85/129) carried SBET medication out of 
those who were prescribed SBET, however overall 216 carried SBET medication, meaning 
131 carried SBET without a SBET prescription, possibly acquiring SBET medication from a 
previous trip or from a friend/family member (30). 
Seven studies provided information on the proportion of SBET carriers experiencing fever, 
varying between 4.6% - 23% (table 2). Among available information on attitude in those with 
fever, 2-100% used SBET when febrile, 0-79.9% consulted a health facility, and among the 
two studies in which travelers were provided mRDT, 50.4% and 57.1% used mRDT when 
febrile. Appropriate response to fever, defined as using SBET, consulting a health facility or 
using mRDT in the case of fever, varied between 23% to 100%. Among travelers using 
SBET, those consulting a health facility thereafter varied; 23/50 in the Nothdurft et al. study 
(28),  6/6 in Schlagenhauf et al. study (15), 94/178 in the Roukens et al. study (authors 
personal communication), 1/5 in the Berthod et al. study (32), and 0/4 in the Ferrara et al 
study (34). While according to our definition we considered that 23% (23/100) had 
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appropriate response to fever in the Vinnemeier et al. study, the authors of the study found 
that only 16% (16/100) had an appropriate response to fever, as they did not count 6 health 
facility visits by travelers that were not within the advised 24 hour period, and two who used 
SBET but did not apply the correct dosage/duration (33). Although disaggregated data was 
not available for the Roukens et al. study, there were already 79.9% (303/379) who had an 
appropriate response to fever by consulting a health facility, without considering SBET or 
mRDT use. 
Two studies found that 87.5% (35/40) and 100% (2/2) travelers used SBET incorrectly, 
defined as ingesting the wrong dosage or duration of SBET medication (28, 33), while in 
three other studies there were no travelers that used SBET incorrectly (15, 32, 34).  
Adverse events to SBET were documented in 6 studies with a proportion between 0 – 33.3% 
of SBET users. The majority of adverse events occurred in the older studies in which 
pyrimethamine, sulfadoxine, mefloquine, halofantrine, or chloroquine were used for SBET 
(15, 26, 28), all malaria medication that were no longer used in the more recent studies (32-
34). 
TABLE 2 
5. Discussion 
In this systematic review and meta-analysis of 11 studies describing SBET use in travelers to 
malaria endemic areas, the pooled overall SBET use prevalence among those who carried 
SBET was 2.5% (95% CI 1.1% - 4.3%). When eliminating the Roukens et al. study which 
included a very different study population, the overall pooled prevalence was 1.8% (95% CI 
0.8%-3.2%).  
A similar systematic review and meta-analysis was recently published without previous 
publication of the protocol. It included only seven studies for the primary outcome despite 
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using similar inclusion criteria, resulting in a similar SBET use prevalence of 2% (95% CI 1-
3%) (35). Among the secondary outcomes analyzed, we included three more studies on the 
reporting of fever, two more studies reporting on the correct dosage/duration of SBET, one 
more study reporting adverse events, and additional analysis on the proportion of SBET use 
among travelers with fever. Our findings are in line with this previous meta-analysis but 
provide supplementary data for primary and secondary outcomes.  
The SBET use prevalence of 2.5%, corresponds to a number needed to carry (NNC) SBET of 
40 for every SBET used (NNC 56 when excluding the Roukens et al. study). As such, it 
seems like a reasonable number for a preventive measure against a potentially lethal disease. 
However when considering a SBET use prevalence of 2.5% for travel destinations where 
malaria incidence should be less than 0.001%, it becomes clear that SBET is mostly used for 
non-malarial infections  (10). In fact Nothdurft et al. and Schlagenhauf et al. found that only 
10.8% (4/37) and 16.7% (1/6) of SBET users actually had malaria (15, 28). Extrapolating this 
to our initial calculation (NNC 40), the number needed to carry becomes 240 to 370 for every 
SBET used for a real malaria infection. Considerably lower than the estimated NNC of 
200’000 for travelers to Southeast Asia by Behrens (4). Moreover, in order to assess the 
relevance of SBET as a preventive strategy, the number needed to prescribe may be a better 
indicator than the number needed to carry, as it better assesses the intervention (prescription 
of SBET). The number needed to prescribe thus would vary between 370 to 981 for every 
SBET used for malaria. Despite this, the SBET approach without the use of mRDT, is 
expected to be used in the case of non-malarial febrile illnesses, as such it is not surprising 
that the NNP or NNC for the treatment of malaria to be so high. 
Among the secondary outcomes analyzed, there was missing data for a number of variables in 
most studies. A high proportion of travelers were found not to adhere to the recommendations 
for SBET use. The first barrier to appropriate SBET use, arose before travel even begun, in 
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which three studies describing a considerable number of travelers who did not buy and carry 
the SBET medication prescribed to them (65.9%, 72.6%, 37.8%) (30, 33, 34).  Two other 
studies not included in this analysis (did not fill inclusion criteria) found that only 61.4%, and 
83% carried their prescribed SBET medication (36, 37). Proportions as low as 37.8% of 
travelers who bought their SBET medication, may suggest different views on the risk of 
malaria among travelers from different countries, and differences in pre-travel advice. Non-
adherence to medical advice in regards to malaria prevention however is not new, and has 
been found to be low for chemoprophylaxis use and mosquito bite prevention despite good 
knowledge of the risk of malaria (38-40). 
Poor adherence to the recommendations in case of fever when carrying SBET occurred 
frequently. WHO guidelines recommend that travelers consult a physician immediately if a 
fever occurs, and only if it is impossible to consult a physician or establish a diagnosis (with 
mRDT for example) within 24 hours, they should ingest SBET and then consult medical care 
thereafter (1). Only in the Roukens et al. study did more than half of the febrile travelers 
consult a health facility, while the second highest proportion of travelers consulting when 
febrile was found in the Berthod et al. study which also equipped travelers with mRDTs (31, 
32). In the remaining studies that did not use mRDTs, travelers seeking a health facility 
ranged between 0-33%.  Although the association between mRDT use and health facility 
consultation is limited by severe heterogeneity and small sample size, it may be explained by 
travelers wanting to consult a health facility due to confirmation of malaria with a positive 
mRDT, or by encouraging travelers to pursue with further investigations in the case of a 
negative mRDT.  Among those seeking health care, not all did so within the recommended 24 
hour limit as demonstrated in the Vinnemeier et al. study in which only 14/20 sought health 
care within this 24 hour limit (33). Schlagenhauf et al. found that while 66.6% (82/123) failed 
to seek medical attention, only 7.3% (9/123) were out of reach (15), similar to a Japanese 
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study on SBET use, which found that only 11% (1/9) of SBET users were out of reach from a 
health facility (41). As such, many travelers may have taken SBET despite being in proximity 
of a health facility. Additionally, among those taking SBET, not all sought health care after 
use, and several took an incorrect dosage schedule of SBET. While the overconsumption of 
antimalarials may not be associated to a significant number of adverse events, as 
demonstrated in the more recent SBET use studies, the false reassurance of taking SBET and 
not consulting may lead to serious complications and delay in diagnosis for other diseases 
mimicking the symptoms of malaria (42, 43). One retrospective analysis on imported malaria 
in France found that the use of SBET was associated to a 3.4 times higher odds of presenting 
severe malaria (44). Finally, some travelers did not adhere to any of the recommendations and 
did not seek health care or take SBET. In certain cases however, travelers were able to 
provide good reasons for their actions (symptoms lasting a few hours, incubation period too 
short) (28, 32) with good outcomes, suggesting that the proposed recommendations to fever 
response may not be appropriate in certain situations.  
Despite poor adherence to SBET use recommendations, there are some studies that provide 
optimism. Roukens et al. demonstrated a high rate of medical attendance in case of fever that 
may be attributed to a formal training employees received on the risks and preventive 
methods against malaria and the presence of a 24 hour a day “Malaria hot line” (31). While 
such training is unrealistic for most pre-travel consultations, it may demonstrate the potential 
for more in-depth pre-travel counselling. Furthermore, the use of mRDT may limit the 
overconsumption of SBET as demonstrated by Berthod et al. who found a low SBET use 
prevalence despite including travelers at a higher risk of malaria. The prescription of mRDT 
however must be accompanied with proper training including written instructions and even a 
blank run in order to avoid inappropriate procedures and misinterpretation of results (45-47). 
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The first and main limitation of this meta-analysis is the heterogeneity of the studies. They 
include studies with different populations (origin, travel duration and destination), study 
design, recruitment methods, study periods (associated with changing malaria epidemiology), 
and use of mRDT. SBET was also used very differently, some as a stand-alone preventative 
method and others in combination with chemoprophylaxis in high risk areas. While these 
differences were expected, exploration of this heterogeneity was not possible due to the low 
number of studies. The quality of the studies varied, with significant bias as defined by the 
mNOS due to the self-reported nature of SBET use studies. . 
In conclusion, SBET use was higher than expected given the estimated risk of malaria in the 
destination countries of travelers, however much lower than expected given the number with 
fever who did not consult a health facility. Adherence to the proposed recommendations for 
SBET use, notably the response to fever, was poor. If the use of SBET is to be pursued, 
modifications must be considered to reflect its current limitations, including better selection 
of travelers at higher risk for malaria, emphasis on the importance of consulting a health 
facilities, and the potential addition of mRDTs. 
6. Figures Legend 
 
Figure 1: 
 Title: Flow diagram of study selection 
 Subheading: SBET: Malaria Standby Emergency Treatment 
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Figure 2: 
 Title: SBET use prevalence among travelers using a random-effects model 
 Subheading: SBET: Malaria Standby Emergency Treatment; CI: Confidence interval; 
ES: Effect size = SBET use prevalence in percentage 
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Table 1: Study characteristics 
Reference Year Study design Type of travelera Number 
of SBET 
carriers 
Study period 
Lobel et al. 
(25)  
1990 Cross-
sectional 
Short-term travelers 
flying back from Kenya 
1’715 1-21 
September 
1987 
Steffen et al. 
(26) 
1990 Cross-
sectional 
Short-term travelers 
flying back from Africa 
17’262 April 1985 to 
July 1988 
Ahlm et al. 
(27) 
1994 Prospective 
cohort study 
Short-term travelers with 
pre-travel consultation in 
Sweden 
182 November 
1990 to May 
1991 
Nothdurft et 
al. (28) 
1995 Prospective 
cohort study 
Short-term travelers with 
pre-travel consultation in 
Germany 
2’867b 1993 
Schlagenhauf 
et al. (15) 
1995 Prospective 
cohort study 
Short-term travelers with 
pre-travel consultation in 
Switzerland 
1’187 March to 
November 
1992 
Rack et al. 
(29) 
2005 Prospective 
cohort study 
Short-term travelers with 
pre-travel consultation in 
Germany 
240 July 2003 to 
June 2004 
Ropers et al. 
(30) 
2008 Cross-
sectional 
Short-term travelers 
flying back to Germany 
216 March to April 
2004 
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from Kenya, Senegal 
and Thailand 
Roukens et 
al. (31) 
2008 Cross-
sectional 
Long-term international 
oilfield service 
employees 
1’643 July to 
September 
2007 
Berthod et 
al. (32) 
2017 Prospective 
cohort study 
Long-term travelers with 
pre-travel consultation in 
Switzerland 
543 February 2012 
to February 
2017 
Vinnemeier 
et al. (33) 
2017 Prospective 
cohort study 
Short-term travelers to 
southeast Asia with pre-
travel consultation in 
Germany 
511 October 2013 
to November 
2014 
Ferrara et al. 
(34) 
2018 Prospective 
cohort study 
Short-term travelers with 
pre-travel consultation in 
Spain 
37 January 2017 
to December 
2017 
a Short- and long-term travelers were defined as the majority of the cohort travelling <3 months or >3 months 
respectively. b Presumption that all those who were prescribed SBET carried SBET 
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Table 2: Secondary outcomes 
Reference Number 
of SBET 
carriers 
SBET 
carriers out of 
those 
prescribed 
SBET (n/N) 
Number 
with fever 
SBET 
users 
SBET use 
among 
those 
febrile 
Health 
facility use 
among 
those 
febrile 
Used 
mRDT 
among 
those 
febrile 
Appropriate 
response to 
fevera 
Adverse 
events to 
SBET 
Incorrect 
dosage or 
duration of 
SBET 
medication 
Lobel et al. (25)  1 715 - n/a 44 - - - - - - 
Steffen et al. (26) 17 262 - n/a 762 - - - - 16.1% 
(123/762
) 
- 
Ahlm et al. (27) 182 - n/a 7 - - - - - - 
Nothdurft et al. 
(28) 
2 867b - 8.1% 
(232/2867) 
40 17.2% 
(40/232) 
- - - 15% 
(6/40) 
87.5% 
(35/40) 
Schlagenhauf et 
al. (15) 
1 187 100% 
(1187/1187) 
10.4% 
(123/1187) 
6 4.9% 
(6/123) 
33.3% 
(41/123) 
- 34.1% 
(42/123) 
33.3% 
(2/6) 
0% (0/6) 
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Rack et al. (29) 240 - n/a 2 - - - - - - 
Ropers et al. (30) 216 65.9% 
(85/129) 
4.6% 
(10/216) 
5 30% 
(3/10) 
- - - - - 
Roukens et al. 
(31) 
1 643 100% 
(1643/1643) 
23% 
(379/1643c) 
178 20.3% 
(77/379c) 
79.9% 
(303/379 c) 
50.4% 
(191/379 c) 
- - - 
Berthod et al. 
(32) 
543 100% 
(543/543) 
16.8% 
(91/543) 
5 5.5% 
(5/91) 
40% 
(36/91) 
57.1% 
(52/91) 
79.1% 
(72/91) 
0% 
(0/50) 
0% (0/5) 
Vinnemeier et al. 
(33) 
511 72.6% 
(511/714) 
19.6% 
(100/511) 
2 2% 
(2/100) 
21% 
(21/100) 
- 23% (23/100) 0% (0/2) 100% (2/2) 
Ferrara et al.  
(34) 
37 37.8% (37/98) 10.8% 
(4/37) 
4 100% 
(4/4) 
0% (0/4) - 100% (4/4) 25% 
(1/4) 
0% (0/2d) 
a Appropriate response being defined as using SBET, consulting a health facility, or using mRDT. b Presumed that all those who were prescribed SBET carried SBET.  c 
Personal communication. d2/4 no data available  
